There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Hookipa Pharma (HOOK – Research Report), Immunovant (IMVT – Research Report) and Amicus (FOLD – Research Report) with bullish sentiments.
Hookipa Pharma (HOOK)
In a report issued on December 21, Andrew Berens from Leerink Partners maintained a Buy rating on Hookipa Pharma, with a price target of $4.00. The company’s shares closed last Friday at $0.72.
According to TipRanks.com, Berens is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Hookipa Pharma is a Strong Buy with an average price target of $5.88.
See Insiders’ Hot Stocks on TipRanks >>
Immunovant (IMVT)
Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant on December 20. The company’s shares closed last Friday at $41.48, close to its 52-week high of $44.70.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunovant with a $49.92 average price target, which is a 27.4% upside from current levels. In a report issued on December 11, Deutsche Bank also initiated coverage with a Buy rating on the stock with a $50.00 price target.
Amicus (FOLD)
In a report issued on December 20, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Amicus, with a price target of $18.00. The company’s shares closed last Friday at $13.60, close to its 52-week high of $14.10.
According to TipRanks.com, Schwartz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Amicus is a Strong Buy with an average price target of $19.71, representing a 48.2% upside. In a report issued on December 19, Morgan Stanley also upgraded the stock to Buy with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HOOK:
- Hookipa Pharma files to sell 15M shares of common stock for holders
- HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
- Hookipa Pharma announces $21.25M equity investment from Gilead
- Biotech Alert: Searches spiking for these stocks today
- HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
